NQO1 and in situ carcinoma: Treatment with SFN before CIS exposure activated the Nrf2 pathway and its target genes (i.e., GCLC and NQO1) and protected from CIS-induced renal cell injury (Guerrero-Beltran et al., 2010a; Atilano-Roque et al., 2016).